NASDAQ:CMMB

Chemomab Therapeutics Stock Forecast, Price & News

$17.16

-0.82 (-4.56 %)

(As of 05/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$16.52

▼

$18.25

50-Day Range

$17.98

▼

$55.00

52-Week Range

$12.32

▼

$168.80

Volume128,711 shs

Average Volume217,468 shs

Market Capitalization$40.10 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive CMMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics (NASDAQ:CMMB) Coverage Initiated at Oppenheimer
May 7, 2021 | americanbankingnews.com

Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Down 2.6%
May 6, 2021 | americanbankingnews.com

Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
April 26, 2021 | finance.yahoo.com

Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing
March 31, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CMMB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.chemomab.com

Phone972 77 331 0156

EmployeesN/A

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares2,337,000

Market Cap$40.10 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.70 out of 5 stars

Medical Sector

266th out of 2,045 stocks

Biotechnology Industry

17th out of 158 stocks

3.5 Analyst's Opinion

Consensus Rating
Chemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.00, Chemomab Therapeutics has a forecasted upside of 144.8% from its current price of $17.16.
Amount of Analyst Coverage
Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Chemomab Therapeutics has received 1 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Chemomab Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Chemomab Therapeutics has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Chemomab Therapeutics and other stocks. Vote “Outperform” if you believe CMMB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CMMB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Chemomab Therapeutics does not currently pay a dividend.
Dividend Growth
Chemomab Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Chemomab Therapeutics (NASDAQ:CMMB) Frequently Asked Questions

Is Chemomab Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chemomab Therapeutics stock.
View analyst ratings for Chemomab Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Chemomab Therapeutics?

Wall Street analysts have given Chemomab Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemomab Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chemomab Therapeutics' next earnings date?

Chemomab Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Chemomab Therapeutics.

What price target have analysts set for CMMB?

1 equities research analysts have issued 1-year target prices for Chemomab Therapeutics' shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Chemomab Therapeutics' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 144.8% from the stock's current price.
View analysts' price targets for Chemomab Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Chemomab Therapeutics' key executives?

Chemomab Therapeutics' management team includes the following people:

Dr. Adi Mor George Ph.D., Co-Founder, CEO, Chief Scientific Officer & Director (Age 39)
Ms. Sigal Fattal, Interim Chief Financial Officer (Age 50)
Dr. Arnon Aharon, Chief Medical Officer (Age 52)

Who are some of Chemomab Therapeutics' key competitors?

Some companies that are related to Chemomab Therapeutics include Longboard Pharmaceuticals (LBPH), Tiziana Life Sciences (TILS), Mereo BioPharma Group plc (MPH.L) (MPH), Circassia Group (CIR), Ampliphi Biosciences (APHB), Helix BioPharma (HBP), ImmunoPrecise Antibodies (IPA), Verseon (VSN), ImmunoPrecise Antibodies (IPA), e-therapeutics (ETX), Agronomics (ANIC), Gain Therapeutics (GANX), Verona Pharma plc (VRP.L) (VRP), Evaxion Biotech A/S (EVAX) and Longeveron (LGVN).
View all of CMMB's competitors.

What is Chemomab Therapeutics' stock symbol?

Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB."

Who are Chemomab Therapeutics' major shareholders?

Chemomab Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.36%).

Which institutional investors are buying Chemomab Therapeutics stock?

CMMB stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd..

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemomab Therapeutics' stock price today?

One share of CMMB stock can currently be purchased for approximately $17.16.

How much money does Chemomab Therapeutics make?

Chemomab Therapeutics has a market capitalization of $40.10 million.

What is Chemomab Therapeutics' official website?

The official website for Chemomab Therapeutics is www.chemomab.com.

How can I contact Chemomab Therapeutics?

The company can be reached via phone at 972 77 331 0156.

This page was last updated on 5/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Chemomab Therapeutics Stock Forecast, Price & News

Adding

Adding

Adding Chemomab Therapeutics Ltd.

About Chemomab Therapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment